How to buy Recursion Pharmaceuticals stock | $19.04

Recursion Pharmaceuticals Inc is a biotechnology business based in the US. Recursion Pharmaceuticals shares (RXRX) are listed on the NASDAQ and all prices are listed in US Dollars. Recursion Pharmaceuticals employs 270 staff and has a trailing 12-month revenue of around 0.00.

Recursion Pharmaceuticals stock price (NASDAQ: RXRX)

Use our graph to track the performance of RXRX stocks over time.

Recursion Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-10-16.

Latest market close	$19.04
52-week range	$17.14 - $42.81
50-day moving average	$23.66
200-day moving average	$28.18
Wall St. target price	$33.17
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.40

Buy Recursion Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Recursion Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Recursion Pharmaceuticals price performance over time

Historical closes compared with the close of $19.04 from 2021-10-15

1 week (2021-10-08)	1.93%
1 month (2021-09-16)	-21.52%
3 months (2021-07-16)	-42.34%
6 months (2021-04-16)	-39.17%

1 year (2020-10-12)	N/A
2 years (2019-10-12)	N/A
3 years (2018-10-12)	N/A
5 years (2016-10-12)	N/A

Recursion Pharmaceuticals financials

Revenue TTM	$8.8 million
Gross profit TTM	$-59,357,000
Return on assets TTM	-26.24%
Return on equity TTM	-54.57%
Profit margin	0%
Book value	$3.82
Market capitalisation	$3.2 billion

TTM: trailing 12 months

Shorting Recursion Pharmaceuticals shares

There are currently 12.0 million Recursion Pharmaceuticals shares held short by investors – that's known as Recursion Pharmaceuticals's "short interest". This figure is 32% up from 9.1 million last month.

There are a few different ways that this level of interest in shorting Recursion Pharmaceuticals shares can be evaluated.

Recursion Pharmaceuticals's "short interest ratio" (SIR)

Recursion Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Recursion Pharmaceuticals shares currently shorted divided by the average quantity of Recursion Pharmaceuticals shares traded daily (recently around 627766.23036649). Recursion Pharmaceuticals's SIR currently stands at 19.1. In other words for every 100,000 Recursion Pharmaceuticals shares traded daily on the market, roughly 19100 shares are currently held short.

To gain some more context, you can compare Recursion Pharmaceuticals's short interest ratio against those of similar companies.

• NGM Biopharmaceuticals (NGM.US): 2.44
• Lixte Biotechnology (LIXT.US): 0.31
• Ultragenyx Pharmaceutical (RARE.US): 10.25

However Recursion Pharmaceuticals's short interest can also be evaluated against the total number of Recursion Pharmaceuticals shares, or, against the total number of tradable Recursion Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Recursion Pharmaceuticals's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Recursion Pharmaceuticals shares in existence, roughly 70 shares are currently held short) or 0.1205% of the tradable shares (for every 100,000 tradable Recursion Pharmaceuticals shares, roughly 121 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Recursion Pharmaceuticals.

Find out more about how you can short Recursion Pharmaceuticals stock.

Recursion Pharmaceuticals share dividends

We're not expecting Recursion Pharmaceuticals to pay a dividend over the next 12 months.

Recursion Pharmaceuticals overview

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc. ; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.

Frequently asked questions

What percentage of Recursion Pharmaceuticals is owned by insiders or institutions?
Currently 17.759% of Recursion Pharmaceuticals shares are held by insiders and 69.383% by institutions. How many people work for Recursion Pharmaceuticals?
Latest data suggests 270 work at Recursion Pharmaceuticals. When does the fiscal year end for Recursion Pharmaceuticals?
Recursion Pharmaceuticals's fiscal year ends in December. Where is Recursion Pharmaceuticals based?
Recursion Pharmaceuticals's address is: 41 South Rio Grande Street, Salt Lake City, UT, United States, 84101 What is Recursion Pharmaceuticals's ISIN number?
Recursion Pharmaceuticals's international securities identification number is: US75629V1044